The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
Collaboration focuses on developing and implementing real-world research to drive patient access to cancer medicines
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Subscribe To Our Newsletter & Stay Updated
